Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

FDA has granted another set of regulatory privileges under its breakthrough devices program. The latest batch is led by breakthrough designations for treatments of lung cancer and bone metastases that are in development at RefleXion Medical and Zetagen Therapeutics.

Ever since the first barcode appeared on a pack of chewing gum in 1974, the now-ubiquitous system has enabled manufacturers, retailers and consumers to quickly and effectively identify, characterize, locate and track products and materials.

Freenome said on Wednesday that it has partnered with German medical technology firm Siemens Healthineers on the identification of blood-based biomarkers for breast cancer detection.

IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer

The creation of nanoscale computers for use in precision health care has long been a dream of many scientists and health care providers. Now, the research paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.

Investigators have determined that high-risk HPV DNA can be detected in saliva in most patients with HPV-driven oropharyngeal cancers at the time of diagnosis.

A large international collaboration led by researchers from the Johns Hopkins Kimmel Cancer Center has identified promising new targets for pancreatic cancer treatment and early diagnosis after examining various aspects of these tumors' genes and proteins.

The Japan Ministry of Health, Labour and Welfare (MHLW), Japan's regulatory agency, has granted approval to the Thermo Fisher Scientific's Oncomine Dx Target Test to be used as a companion diagnostic to identify patients with RET-fusion positive non-small cell lung cancer (NSCLC).

A federal jury on Friday ruled that Qiagen willfully infringed two patents owned by ArcherDx (now part of Invitae) and Massachusetts General Hospital and ruled that Qiagen must pay royalties and lost profits totaling about $4.7 million.